Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib’s efficacy

A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

Exercise is good for health — but why? A study in rats offers insight

It’s widely known that exercise is beneficial for health. Yet science doesn’t have a clear understanding of what makes moving so good for us, including

May 1, 2024

Colchicine vs Afib; Winter Spike in Cardiac Arrests; Cardiologist Stabbed at Home

The anti-inflammatory colchicine, recently approved for cardiovascular prevention (under the trade name Lodoco), appeared to offer protection from postoperative atrial fibrillation in a meta-analysis. (EP

June 28, 2023

MAPS Public Benefit Corporation Announces Oversubscribed Series A Financing and Renames to Lykos Therapeutics | Psychedelic Invest

Funding comes from mission-aligned and institutional investors to support regulatory and pre-launch activities for investigational MDMA-assisted therapy for post-traumatic stress disorder (“PTSD”) Company rebrands and

January 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.